Ovid Therapeutics Inc. (OVID) Income Statement
OVID 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOVID revenue and net income
Where OVID's revenue goes
2025Each bar shows an amount and its share of revenue. OVID kept −240.1% of revenue as net income.
OVID profit margins
OVID growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1,181.3% | +69.0% | −10.5% | — |
| Gross profit | +1,128.3% | +66.6% | −11.2% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OVID quarterly EPS vs estimates
Ovid Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.08).
OVID income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $566,000 | $392,000 | $1.5M | $208.4M | $12.6M | $0 | $0 | $0 | $0 |
| Cost of revenue | $300,000 | $600,000 | $1.6M | $1.4M | $0 | $0 | $255,000 | $141,733 | $80,310 | $56,512 |
| Gross profit | $7.0M | $566,000 | $392,000 | $1.5M | $208.4M | $12.6M | −$255,000 | −$141,733 | −$80,310 | −$56,512 |
| Research & development | $25.6M | $36.8M | $28.6M | $24.6M | $46.9M | $63.4M | $42.2M | $33.8M | $50.0M | $9.6M |
| Sales, general & admin | $24.1M | $25.7M | $29.6M | $32.4M | $37.2M | $30.6M | $19.3M | $19.1M | $15.0M | $12.9M |
| Total operating expenses | $49.4M | $62.5M | $59.7M | $57.1M | $84.2M | $94.0M | $61.4M | $52.9M | $65.0M | $22.5M |
| Operating income | −$42.4M | −$61.9M | −$59.3M | −$55.5M | $124.2M | −$81.4M | −$61.4M | −$52.9M | −$65.0M | −$22.5M |
| Interest income | — | $3.9M | $4.9M | — | — | — | $948,224 | $952,073 | $201,509 | $120,820 |
| Interest expense | — | — | — | $2.8M | $46,794 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$17.4M | −$26.4M | −$52.3M | −$54.2M | $124.2M | −$81.0M | −$60.5M | −$52.0M | −$64.8M | −$22.4M |
| Income taxes | — | — | $5 | −$2.8M | $1.3M | −$306,848 | −$1.2M | $951,725 | −$80,310 | −$950 |
| Net income | −$17.4M | −$26.4M | −$52.3M | −$51.4M | $122.8M | −$80.7M | −$59.3M | −$52.0M | −$64.8M | −$22.4M |
| EBITDA | −$17.1M | −$57.8M | −$57.0M | −$54.2M | $124.4M | −$81.1M | −$61.2M | −$52.8M | −$64.9M | −$22.5M |
| EPS (diluted) | −$0.31 | −$0.38 | −$0.75 | −$0.74 | $2.03 | −$1.40 | −$1.58 | −$2.12 | −$4.88 | −$1.14 |
| Gross margin | 95.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | −585.2% | −10,933.7% | −15,122.7% | −3,696.4% | 59.6% | −645.4% | — | — | — | — |
| Net margin | −240.1% | −4,670.1% | −13,351.8% | −3,421.0% | 58.9% | −639.8% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $733,000 | $0 | $718,000 | $132,000 | $6.3M | $130,000 | $76,000 | $173,000 | $169,000 | $148,000 | $142,000 | $109,000 |
| Cost of revenue | $16,000 | $35,000 | $44,000 | $17,000 | $99,000 | $284,000 | $0 | $169,000 | $148,000 | $136,000 | $401,392 | $402,461 |
| Gross profit | $733,000 | −$35,000 | $718,000 | $132,000 | $6.3M | $130,000 | $76,000 | $173,000 | $169,000 | $148,000 | $142,000 | $109,000 |
| Research & development | $10.0M | $11.2M | $6.6M | $5.9M | $6.5M | $6.7M | $5.9M | $7.9M | $12.6M | $10.4M | $10.6M | $5.3M |
| Sales, general & admin | $6.2M | $6.7M | $6.4M | $6.8M | $4.9M | $6.0M | $6.8M | $5.5M | $8.1M | $7.2M | $6.5M | $6.8M |
| Total operating expenses | $16.4M | $17.8M | $13.0M | $12.7M | $11.3M | $12.7M | $10.8M | $13.4M | $20.7M | $17.6M | $18.3M | $12.1M |
| Operating income | −$15.7M | −$17.8M | −$12.3M | −$12.5M | −$5.1M | −$12.6M | −$10.7M | −$13.2M | −$20.5M | −$17.4M | −$18.2M | −$12.0M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.54B | — |
| Income before taxes | −$15.0M | −$17.0M | $9.7M | −$12.2M | −$4.7M | −$10.2M | −$9.3M | −$14.0M | $8.5M | −$11.7M | −$15.3M | −$11.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | $92,724 | −$2 | $213 |
| Net income | −$15.0M | −$17.0M | $9.7M | −$12.2M | −$4.7M | −$10.2M | −$9.3M | −$14.0M | $8.5M | −$11.7M | −$15.3M | −$11.3M |
| EBITDA | −$15.4M | −$17.8M | $9.7M | −$12.1M | −$4.6M | −$10.1M | −$10.8M | −$13.8M | $8.7M | −$11.6M | −$16.1M | −$11.1M |
| EPS (diluted) | −$0.08 | −$0.12 | $0.06 | −$0.17 | −$0.06 | −$0.14 | −$0.13 | −$0.20 | $0.12 | −$0.17 | −$0.22 | −$0.16 |
| Gross margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −2,141.6% | — | −1,712.1% | −9,487.1% | −80.9% | −9,653.8% | −14,107.9% | −7,645.1% | −12,140.2% | −11,768.2% | −12,808.5% | −11,035.8% |
| Net margin | −2,047.6% | — | 1,345.8% | −9,210.6% | −74.7% | −7,873.1% | −12,175.0% | −8,096.0% | 5,042.0% | −7,901.4% | −10,790.1% | −10,323.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OVID's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OVID financial results
In fiscal year 2025 (ended December 31, 2025), Ovid Therapeutics reported revenue of $7.3 million, up 1,181.3% from the year before. It had a net loss of $17.4 million, a net profit margin of −240.1%. Diluted earnings per share came to −$0.31. Over five years revenue grew at an average rate of −10.5% a year.
See the OVID stock overview for the latest quote and news, or the OVID chart for price history and technical indicators.
OVID income statement FAQ
What is Ovid Therapeutics's annual revenue?
Ovid Therapeutics reported total revenue of $7.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 1,181.3% from $0.6 million the previous year.
Is Ovid Therapeutics profitable?
No. Ovid Therapeutics reported a net loss of $17.4 million in fiscal 2025, a net profit margin of −240.1%; its operating margin was −585.2%.
What is Ovid Therapeutics's gross margin?
Ovid Therapeutics's gross margin was 95.9% in fiscal 2025: for every $100 of revenue, Ovid Therapeutics kept $96 after the direct cost of its products and services.
How much does Ovid Therapeutics spend on research and development?
Ovid Therapeutics spent $25.6 million on research and development in fiscal 2025, 352.8% of revenue.
How fast is Ovid Therapeutics growing?
Revenue grew −10.5% a year on average over the last five fiscal years, from $12.6 million to $7.3 million.
What are Ovid Therapeutics's earnings per share?
Ovid Therapeutics earned $-0.31 per diluted share in fiscal 2025, compared with $-0.38 a year earlier.
When will Ovid Therapeutics report its next earnings?
Ovid Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Ovid Therapeutics's fiscal year end?
Ovid Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.